Adults and children are prescribed as detoxification therapy when: acute poisoning of various origins (strong and poisonous substances, drugs and alcohol, alkaloids, heavy metal salts); intoxication of various origins acute intestinal infections of any origin (toxicoinfection, salmonellosis, dysentery, dysbacteriosis); purulent-septic diseases; Allergy, atopic dermatitis, urticaria eczema; viral hepatitis A and B, toxic hepatitis, liver cirrhosis, hepatocholecystitis; glomerulonephritis, pyelonephritis, polycystic kidney disease; malignant diseases (for detoxification before and after surgery, during radiation or chemotherapy).
Enterosgel 135 g. Composition
active substance: 100 g of paste contains 70 g of methylsilicic acid hydrogel;
Enterosgel 135 g. excipient: purified water.
Enterosgel 135 g. Dosage form
Basic physical and chemical properties: homogeneous pasty mass of white color, odorless.
Enterosorbents. ATX code A07B.
Enterosgel is an inert organosilicon compound. When applied, it has a sorption effect. The drug effectively adsorbs medium-molecular toxic substances of exo- and endogenous origin, products of incomplete metabolism, incorporated radionuclides and naturally removes them from the body.
Enterosgel eliminates the manifestations of toxicosis, improves the functions of the intestines, liver, kidneys, and normalizes blood and urine parameters.
Covering the mucous membrane of the stomach and intestines, Enterosgel protects it from erosive processes, improves local immunity.
Enterosgel is not absorbed from the intestines and does not undergo metabolic or chemical transformations.
As part of complex detoxification therapy for chronic renal failure; with toxic hepatitis, viral hepatitis A, B, liver cirrhosis and cholestasis of various etiologies; with enterocolitis, colitis, diarrhea, gastritis with low acidity, with alcohol and drug poisoning; for allergic and skin diseases (diathesis, neurodermatitis); with burn intoxication; purulent-septic and inflammatory processes, accompanied by intoxication; toxicosis of pregnant women in the first half of pregnancy in the complex therapy of intestinal dysbiosis.
Acute intestinal obstruction.
Interaction with other medicinal products and other forms of interaction
The drug may reduce the effect of other drugs used with it. Concomitant use of drugs belonging to the class of bile acid sequestrants, such as cholestyramine, is not recommended due to the increased likelihood of constipation.
The drug should be used together with silver preparations.
Subject to the method of application (Enterosgel and drugs are taken at intervals of 1.5-2 hours), the drug can be used in complex therapy with other drugs and prophylactic agents, including prebiotics and probiotics (bifidum-, lactobacilli), phytopreparations, adaptogens , immunomodulators.
Application during pregnancy or lactation.
The drug can be used during pregnancy or lactation. Use should be limited to pregnant women with a tendency to constipation.
The ability to influence the reaction rate when driving vehicles or other mechanisms.
Does not affect.